Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
Status:
Terminated
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of neoadjuvant aromatase inhibitor plus ovarian
suppression with chemotherapy in premenopausal patients with hormone receptor-positive breast
cancer.